enasidenib

Ligand id: 8960

Name: enasidenib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 108.74
Molecular weight 473.14
XLogP 5.19
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Having completed Phase 3 clinical trial, enasidenib (AG-221) was approved by the US FDA in August 2017, for the treatment for IDH2 mutation positive acute myeloid leukemia (AML- see trial NCT02577406). The presence of IDH2 mutations must be confirmed using the companion diagnostic, RealTime IDH2 Assay. A Phase 2 trial in patients with IDH2 mutation positive advanced solid tumours (including glioma) and angioimmunoblastic T-cell lymphoma has been completed (NCT02273739).
Mechanism Of Action and Pharmacodynamic Effects
AG-221 is believed to prevent the formation of IDH2 homodimers by binding to the inter-subunit contact region. This action prevents the formation of functional dimers of mutant IDH2 enzymes which would produce the oncometabolite 2-HG.